Changes in the Utilization of Short-Chain Peptides in Liver Pathology

Zhuraeva M.A.^1, , Ravzatov J.B.¹ and Ashuralieva M. A.¹

¹Department of Family Medicine No. 1 of the Andijan State Medical Institute, Doctor of Medical Sciences, Uzbekistan

Cite this paper:
Zhuraeva M.A., Ravzatov J.B. and Ashuralieva M. A.. Changes in the Utilization of Short-Chain Peptides in Liver Pathology. American Journal of Medical Sciences and Medicine. 2022; 10(2):65-68. doi: 10.12691/ajmsm-10-2-5

Abstract

The effect of intraportal administration of trypsin on the degree of utilization of cholecystokinin short-chain peptide by the liver by the liver was studied in rats according to the degree of its influence on the secretory function of the pancreas. Studies were conducted on 56 rats in 8 series, 7 acute experiments in each series. Conclusions were made: in rats, the liver utilizes short-chain peptide CCK-8. Trypsin, when co-administered with CCK-8 in the peripheral vein, slightly increases the secretory activity of the pancreas and significantly when administered into the portal vein, which indicates that trypsin can reduce the ability of the liver to utilize the CCK-8 short chain peptide. This fact confirms the involvement of the liver in the change in utilization of short-chain peptides, which is one of the mechanisms regulating pancreatic secretory activity. Trypsin is also involved in these mechanisms of regulation of the activity of the digestive glands, which is new evidence of the existence of a physiological mechanism of the relationship between the gastrointestinal tract and the liver.

Keywords:
short chain peptide trypsin liver decreases pancreatic proteases

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Ramachandran R., Hollenberg M.D. Proteinases and signaling: pathophysiologi-cal and therapeutic implications via PARs and more // Br. J. Pharmacol. –2008.– Vol. 153. – P. 263-282.
[2]	Aleinik V.A., Babich S.M. The effect of various doses of trypsin on the change in liver utilization of pentagastrin // Vestnik TMA, 2013, No. 1, S. 13-16.
[3]	Babich S. M., Aleinik V.A. Changes in gastric secretion with the introduction of pentagastrin and leu-enkephalin into the peripheral and portal veins // Journal of Postgraduate Doctor, Voronezh, 2010.- No. 5.2 (42) .- P.252-257.
[4]	Bhattacharyya R. et al. A prospective pilot study of the prevalence of pancreatic disease in patients with alcohol related liver disease using faecal elastase-1 //Gut, 2011, Т.60, Suppl 1, С. A238-A238.
[5]	Kawabata A., Matsunami M., Sekiguchi F. Gastrointestinal roles for proteinase-activated receptors in health and disease. Review // Br. J. Pharmacol.– 2008.– Vol. 153.– P. 230-240.
[6]	Kalaitzakis E, Bjornsson E. Hepatic encephalopathy in patients with liver cirrhosis: is there a role of malnutrition//World J Gastroenterol, 2008, 14: 3438-3439.
[7]	Ossovskaya V.S., Bunnett N.W. Protease-Activated Receptors: Contribution to Physiology and Disease// Physiol Rev.- 2004.- Vol.84. – P. 579-621.
[8]	Katakura Y. et al. Pancreatic involvement in chronic viral hepatitis //World Journal of Gastroenterology: WJG, 2005, Т.11, №23, С. 3508.
[9]	Korotko G. F., Aleinik V. A., Kurzanov A. N., Khamrakulov Sh. Trypsinogen as a modifier of peptidergic effects on the secretion of the gastric and pancreas // Ros. fiziol. journal them. I. M. Sechenov. - 1996 - T. 82. No. 8-9. - S. 87-95.
[10]	Hoffmaster KA, Zamek-Gliszczynski MJ, Pollack GM, Brouwer KL. Hepatobiliary disposition of the metabolically stable opioid peptide [D-Pen2, D-Pen5]-enkephalin (DPDPE): pharmacokinetic consequences of the interplay between multiple transport system//J. Pharmacol. Exp. Ther., 2004, vol.311(3), P.1203-10.